bannerhome
 
 

ABOUT

PDS Biotech aims to advance and expand its proprietary pipeline programs independently or in collaboration with renowned research institutions and pharmaceutical companies.

Key commercial partners:

merck nih

Strategic Research Collaborations with:

NCI Stacked COLOR nih nih niaid mayo

PDS Biotech is dedicated to maximizing the full potential of the Versamune® and Versamune® plus PDS0301 platforms in oncology and the Infectimune™ platform in infectious diseases.

Versamune® and Versamune® plus PDS0301 are proprietary T cell activating platform technologies which induce a strong immune response in combination with tailored antigens to fight cancer.

Infectimune™ is a proprietary T cell immune activating platform technology designed to train the immune system to better protect against infectious diseases.

We are open to strategic partnerships which reflect the value-creating potential of our T cell activating platforms to provide performance-related downstream revenues, while preserving future growth opportunities for PDS Biotech.

Please contact our This email address is being protected from spambots. You need JavaScript enabled to view it.

Receive Email Alerts

Join our mailing list to receive the latest news and updates from our team.

Sign up

pdf